ECT denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for ect are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Electroconvulsive Therapy (ECT) as "Not FDA-Approved"

Electroconvulsive therapy is delivered using FDA-regulated devices that have received marketing authorization. A "not FDA-approved" denial for ECT from Cigna is almost always based on a misclassification — either the claim was flagged by an automated system that misread the procedure code, the denial reflects confusion about the difference between FDA device authorization and drug approval, or Cigna's reviewer applied a policy that uses "FDA-approved" language to a procedure rather than a product. In rare cases, the denial may relate to a specific ECT protocol or device variant that is newer and under a different regulatory status.

## Why This Denial Is Appealable

FDA authorization for ECT delivery devices is a matter of public record. If Cigna's denial rests on an incorrect factual premise — that ECT devices lack FDA authorization — that premise can be directly rebutted with publicly available FDA records. Under ERISA §503 and ACA §2719, the plan must conduct a full-and-fair individualized review; a denial based on a factual error is not a full-and-fair review. The Mental Health Parity and Addiction Equity Act also applies: Cigna may not impose an FDA-approval barrier on mental health procedures that it does not apply to analogous medical or surgical procedures.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice. Specifically request the clinical rationale and the regulatory basis for the "not FDA-approved" determination.
• External review: Available after final internal denial. An independent IRO will evaluate whether the FDA-status characterization was accurate. The standard external-review window is approximately four months from the final adverse determination; expedited review is available when delay would jeopardize health.

## Concrete Appeal Steps

1. Confirm the FDA regulatory status of the specific ECT device used — FDA device-clearance information is publicly available at fda.gov. Print or save the relevant FDA record. 2. Obtain Cigna's medical coverage policy for ECT and identify any FDA-status language in that policy. 3. Have your treating psychiatrist write a letter confirming that the ECT procedure was performed with an FDA-authorized device for an established clinical indication. 4. Submit a written rebuttal citing the FDA record, Cigna's own coverage policy (if it acknowledges ECT as established), and the factual error in the denial. 5. Raise MHPAEA: request that Cigna identify any analogous medical or surgical procedure for which it applies the same FDA-approval barrier.

## Documentation to Gather

• Diagnosis confirmation: Psychiatric evaluation notes establishing the clinical indication for ECT.
• Prior-treatment history: Records supporting the clinical appropriateness of ECT for this patient's situation.
• Clinical severity: Psychiatrist documentation of current status and the medical urgency of ECT access.
• Prescriber medical-necessity letter: A letter from the treating psychiatrist confirming the FDA-authorized status of the device and procedure and rebutting the experimental or unapproved characterization.
• FDA regulatory record: A printout of the FDA's device-clearance record for the ECT device used.
• Cigna's own ECT policy: Printed copy with relevant passages highlighted, to demonstrate internal inconsistency if the policy acknowledges ECT as established.

## Criteria-Mapping Structure

Your appeal should be structured around two columns: Cigna's denial rationale on the left, and the factual rebuttal on the right. For the FDA-approval claim, pair it with the FDA clearance record and the prescriber's confirmation. For any additional criteria cited in the denial, pair each with the specific chart evidence that satisfies it. A factually precise, source-cited rebuttal is the most effective format for this type of denial.